Establishment of Cohort Under the Guidance of the Pathogenesis of Cancer Toxin in Traditional Chinese Medicine

Study Design Types: A prospective, multicenter, observational study.

Observation Content:1.Healthy Individuals:General Information (Demographic Data), Traditional Chinese Medicine Physical Quality Scale, Biological Samples (Fecal, Blood, Tongue Coating, Tongue Appearance Photos, Tissues). 2.Malignant Tumor Patients: General Information (Demographic Data, Disease Information, ECOG Performance Status Score, MDASI Anderson Symptom Inventory), Traditional Chinese Medicine Cancer Toxin Syndrome Scale, Traditional Chinese Medicine Physical Quality Scale, Laboratory and Examination Data, Biological Samples (Fecal, Blood, Tongue Coating, Tongue Appearance Photos, Tissues).

Observation Time Points:1.Healthy Individuals: At the time of enrollment. 2.Malignant Tumor Patients: At the time of enrollment, 1 month after enrollment, every 3 months thereafter until tumor progression.

Inclusion criteria

Inclusion criteria

for healthy individuals:

• Age ≥ 18 years old;
• Informed consent and signed informed consent form.

Inclusion criteria

for patients with malignant tumors:

• Patients with malignant tumors diagnosed by pathology or cytology;
• Advanced stage patients who have not received modern medical treatment in the past, or early to mid-stage patients who have completed postoperative radiochemotherapy for ≥ 1 month;
• Age ≥ 18 years old;
• Informed consent and signed informed consent form.

Exclusion criteria

Exclusion criteria

for healthy individuals:

• Patients with malignant tumors diagnosed by pathology or cytology;
• Those who have taken any antibiotics/probiotics within 1 month before biological sample collection;
• Those with other immune or infectious diseases;
• Those with severe damage to the heart, liver, lungs, or kidney functions;
• Pregnant women, or those with mental illnesses such as depression or schizophrenia;
• Those deemed ineligible for the study by the researcher.

Exclusion criteria

for patients with malignant tumors:

• Patients with multiple primary cancers;
• Those who have taken any antibiotics/probiotics within 1 month before biological sample collection;
• Those with other immune or infectious diseases;
• Those with severe damage to the heart, liver, lungs, or kidney functions;
• Pregnant women, or those with mental illnesses such as depression or schizophrenia;
• Those deemed ineligible for the study by the researcher.